Amphastar Pharmaceuticals, Inc.

AMPHNASDAQHealthcare● Active

$19.50

$-0.24(-1.22%)

Market Cap$859811921

P/E Ratio—

52W High$31.26

52W Low$16.65

Avg Volume610K

Open$19.75

Beta0.90

Cash on Hand Financials Revenue

Amphastar Pharmaceuticals, Inc. (AMPH) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

AMPH · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$282.8M▲ +27.6% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$170.2M

cashAndCashEquivalents

Short-Term Investments

$112.6M

shortTermInvestments

YoY Change vs Prior Year

+27.6%

vs prior fiscal year

Latest Quarter

$294.4M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$282.8MCash on Hand

Total Debt$656.0MTotal Debt

Net Cash / Net Debt−$373.2MNet Debt Position

Cash vs Debt Ratio

Cash 30%Amphastar Pharmaceuticals, Inc. cash as % of market cap: 32.89%% · MCap $1BDebt 70%

Amphastar Pharmaceuticals, Inc. carries a net debt position of $373.2M. Total debt ($656.0M) exceeds cash on hand ($282.8M). Amphastar Pharmaceuticals, Inc. cash vs debt ratio: 30% cash / 70% debt.

Net Cash = Cash & ST Investments − Total Debt$282.8M − $656.0M = −$373.2M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

AMPH annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

AMPH cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$282.8M+27.6%

Dec 31, 2024FY$221.6M-13.7%

Dec 31, 2023FY$256.8M+46.1%

Dec 31, 2022FY$175.8M+28.6%

Dec 31, 2021FY$136.7M+29.4%

AMPH cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

AMPH vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Amphastar Pharmaceuticals, Inc.YOU

AMPH

$282.8M$857M33.0%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Amphastar Pharmaceuticals, Inc. (AMPH) cash on hand as of December 31, 2025 is $282.8M, comprising $170.2M in cash and cash equivalents (CCE) plus $112.6M in short-term investments — reported as Amphastar Pharmaceuticals, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Amphastar Pharmaceuticals, Inc. cash reserves or cash position.

Amphastar Pharmaceuticals, Inc. annual cash on hand history shows increased +27.6% in 2025: increased +27.6% in 2025. Amphastar Pharmaceuticals, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Amphastar Pharmaceuticals, Inc. carries total debt of $656.0M against cash of $282.8M, resulting in a net debt position of -$373.2M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

AMPH cash on hand · 5 questions

As of December 31, 2025, Amphastar Pharmaceuticals, Inc. (AMPH) has $282,812,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $170,177,000 in cash and cash equivalents (CCE) plus $112,635,000 in short-term investments. Latest quarter (March 31, 2026): $294,386,000. Data sourced from the annual 10-K filing via FMP.

AMPH cash on handAMPH cash reservesAMPH cash 2025how much cash does AMPH have

▸ Source: FMP /balance-sheet-statement · US GAAP · Amphastar Pharmaceuticals, Inc. · Amphastar Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025